FY2025 · ended Dec 31, 2025 · Revenue $2.98M, +19.0% YoY · Filed Mar 12, 2026
Xenetic Biosciences, Inc. (XBIO) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.0 million and a net loss of $2.7 million.
Revenue (TTM)
$3.26M
+33.3% vs year-ago TTM
Net income (TTM)
$-2.48M
+19.7% vs year-ago TTM
Operating cash flow (TTM)
$-2.31M
+8.2% vs year-ago TTM
Free cash flow
$-6.46M
-535.3% vs prior year
EPS (TTM)
$-1.19
+40.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.29M
+0.0% vs prior year
Net cash
$11.47M
FY 2020
Operating margin
-81.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Framingham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1534525
- Former names
- General Sales & Leasing, Inc. (until Jan 10, 2014); GENERAL AIRCRAFT INC. (until Feb 12, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M |
| Diluted EPS | -$1.58 | -$2.57 | -$2.71 | -$4.61 | — |
| Operating cash flow | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M |
| Total liabilities | $968,025 | $894,263 | $809,585 | $1.1M | $1.4M |
| Stockholders' equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M |
| Cash and investments | $7.9M | $6.2M | $9.0M | $13.1M | $18.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 16, 2026 | Sep 14, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
May 13, 2026 | May 13, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
All 484 Xenetic Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.